Ozempic vs Zepbound: Labels and Trial Evidence (2026)

The most important distinction is the brand label

A search for these names often sounds like a request to identify a winner. That framing skips the most consequential fact: the current U.S. labels describe different primary treatment lanes. Comparing the names without first separating those lanes can make an evidence summary look simpler than it is.

Ozempic is semaglutide injection. Its current prescribing information describes a GLP-1 receptor agonist used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The same label contains specified cardiovascular and chronic-kidney-disease risk-reduction indications for defined groups of adults with type 2 diabetes. [S1]

Zepbound is tirzepatide injection. Its current prescribing information describes a GIP and GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition. It also has an indication for moderate-to-severe obstructive sleep apnea in adults with obesity. [S2]

Those statements are brand-specific. The Ozempic label captured for this guide does not establish Ozempic as a chronic weight-management brand. The Zepbound label captured here does not establish Zepbound as a type 2 diabetes brand. A clinician may have a broader medical conversation, but this article does not convert one brand’s evidence or indication into the other brand’s claim.

This boundary is easier to see when related brand families are separated. Our Ozempic and Wegovy label guide explains why sharing semaglutide does not merge two brand labels. The Mounjaro and Zepbound label guide applies the same principle to tirzepatide. These are label-education links, not treatment endorsements, and this page imports no price information from them.

At-a-glance label comparison

The table below is intentionally about captured label facts, not personal suitability. It avoids a “better” column because a universal verdict would erase diagnosis, indication, contraindications, other medicines, and the limits of the available head-to-head trial.

The “additional purposes” row should not be read as a contest between unlike outcomes. A cardiovascular indication in a defined diabetes population and an OSA indication in adults with obesity answer different clinical questions. Putting them in one winner score would be misleading.

There is also no access verdict in the table. A product’s indication, a clinician’s assessment, a health plan’s coverage policy, a pharmacy’s availability, and the amount a person may owe are separate layers. This source packet supports the label layer; it does not contain current official price evidence or an individual plan determination.

What the Ozempic label establishes

Ozempic’s first captured indication is glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. The label then adds reduction of major adverse cardiovascular-event risk for adults with type 2 diabetes and established cardiovascular disease. It also adds reduction of sustained eGFR decline, end-stage kidney disease, and cardiovascular death for adults with type 2 diabetes and chronic kidney disease. [S1]

The repeated type 2 diabetes language is important. It defines the populations attached to those risk-reduction claims. This article does not shorten the wording into a broad statement that Ozempic prevents cardiovascular or kidney events for everyone, and it does not transfer those indications to a different semaglutide or tirzepatide brand.

For someone researching a diabetes question, that means the comparison should begin with the actual objective. Is the conversation about glycemic control, established cardiovascular disease, chronic kidney disease, or something else? Those questions cannot be collapsed into a generic interest in body-weight change. Our Mounjaro and Ozempic comparison provides another label-first view of the diabetes-brand lane.

For someone researching chronic weight management, the Ozempic name creates a different evidence problem. The captured Ozempic indication language does not name chronic weight management. That does not permit this guide to use a semaglutide obesity trial as though every semaglutide regimen were an Ozempic regimen. Molecule, brand, regimen, indication, and trial population must stay distinct.

What the Zepbound label establishes

The current Zepbound prescribing information places the brand in combination with reduced-calorie diet and increased physical activity. Its captured weight-management indication covers adults with obesity and adults with overweight when at least one weight-related comorbid condition is present. The label describes reducing excess body weight and maintaining weight reduction long term. [S2]

Zepbound’s other captured indication is treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This is not an indication for every person with sleep apnea, and the wording should not be separated from the adult-with-obesity population in the label. [S2]

The label also says coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. That is a product-use boundary, not an invitation for a reader to redesign a regimen. This article therefore provides no combining, sequencing, or changing-treatment instructions. [S2]

These label facts can help a reader prepare better questions, but they do not determine eligibility. Terms such as obesity, overweight with a comorbid condition, and moderate-to-severe OSA are part of a clinical assessment. A general web article does not have the measurements, diagnoses, medical history, or complete medicine list required to apply them to an individual.

Ingredients and drug classes

The ingredient distinction is straightforward but should not be overstated. The Ozempic prescribing-information heading identifies semaglutide. The Zepbound heading identifies tirzepatide. The Ozempic label describes GLP-1 receptor agonism, while the Zepbound label describes both GIP and GLP-1 receptor agonism. [S1][S2]

That mechanism language helps explain why the products are not chemically identical. It does not, on its own, prove which product would work better for a person, which would be tolerated better, or which would be covered. Mechanistic complexity is not the same thing as a patient-specific outcome.

This layered reading prevents two common errors. The first is brand substitution: treating any semaglutide evidence as Ozempic evidence or any tirzepatide evidence as Zepbound evidence. The second is population substitution: assuming evidence from adults with obesity without type 2 diabetes answers a treatment question for adults with type 2 diabetes.

What SURMOUNT-5 can and cannot tell us

SURMOUNT-5 matters because it is a phase 3b, open-label, controlled obesity trial of tirzepatide and semaglutide. It randomly assigned adults with obesity without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg), administered once weekly for 72 weeks. [S3]

That design does not make the trial a direct test of the current Ozempic and Zepbound brand labels. The semaglutide regimen and obesity population must remain attached to the trial, rather than being relabeled as an Ozempic arm. The trial also cannot answer a glycemic-control, cardiovascular-risk, or chronic-kidney-disease question for the Ozempic label populations captured above. [S3]

The official PubMed abstract reports that 751 participants underwent randomization. At week 72, the least-squares mean percent weight change was -20.2% (95% CI, -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). Eli Lilly funded the trial. These are population-level results from the studied regimens, not a forecast for any individual, and the semaglutide arm must not be relabeled as Ozempic. [S3]

A responsible trial discussion therefore has two parts. It should report what was studied, and it should state what was not studied. Omitting the second part would encourage readers to map an obesity-regimen result onto an Ozempic diabetes-brand question that the trial was not designed to answer.

It is also inappropriate to combine the trial and labels into a single “best” score. The labels establish approved purposes and safety information. The trial evaluates a specified comparison in a specified population. Neither source layer provides a plan-specific coverage decision or an individual recommendation.

Common adverse-reaction lists

Both captured labels list nausea, vomiting, diarrhea, abdominal pain, and constipation among common adverse reactions reported in at least five percent of treated patients. Ozempic’s captured highlights list those five items. Zepbound’s captured list also includes dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. [S1][S2]

The lists overlap, but a label-list comparison is not a comparative-safety trial. The excerpts use product-specific clinical programs and do not establish that a reaction is more likely, less likely, more severe, or more manageable for an individual on one brand. A shorter printed list is not proof of superior tolerability.

Readers looking for label context can use the dedicated Ozempic side-effects guide and Zepbound side-effects guide. Those links do not replace the complete current prescribing information or a clinician’s review of symptoms and history.

Contraindications and warning topics

Both captured labels include contraindication language involving a personal or family history of medullary thyroid carcinoma, or MTC, and Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Both also identify serious hypersensitivity to the active ingredient or product excipients as a contraindication. [S1][S2]

The similarity is useful for preparing a history, not for self-screening. A person may not know whether a past reaction qualifies as serious hypersensitivity, whether a family thyroid-cancer history was MTC, or whether an endocrine diagnosis was MEN 2. Those are reasons to bring records and questions to a licensed clinician or pharmacist.

The captured labels also say the products are not recommended in patients with severe gastroparesis, and both say they delay gastric emptying in language that raises potential interaction questions for oral medicines. Both captured highlights include acute-kidney-injury-due-to-volume-depletion and pulmonary-aspiration-during-anesthesia-or-deep-sedation topics. [S1][S2]

Some captured topics are product-specific in this packet. The Ozempic highlights tell patients with a history of diabetic retinopathy to be monitored. The Zepbound highlights identify acute gallbladder disease as reported in clinical trials. These observations should remain tied to their labels; the absence of a topic from this short comparison is not proof that it is absent from the complete information. [S1][S2]

This is not a complete warning inventory. The safest next reading is the full current prescribing information, including boxed warning, contraindications, warnings and precautions, interactions, use in specific populations, and patient counseling information. A summary cannot capture every qualification.

Urgent or severe symptoms require appropriate professional evaluation rather than a web comparison. This page does not diagnose a reaction, decide whether a medicine caused it, or tell a reader whether to continue or discontinue a prescription.

Access and coverage are separate questions

Label alignment does not guarantee that a clinician will prescribe a product, that a plan will cover it, that a pharmacy will have it, or that a person’s cost will fit a budget. Each layer can have its own documentation and timing.

A useful access conversation begins by naming the exact brand and the exact clinical purpose under discussion. A plan policy for a diabetes brand may not answer a question about a chronic weight-management brand. Likewise, a formulary listing does not establish that a member meets the policy’s criteria.

Because this source packet includes no current official price material, the article gives no numeric cost comparison. It also does not imply that a coupon, direct-pay pathway, or insurance benefit is available. For nonnumeric context on plan verification, see the Zepbound insurance coverage guide.

These questions are designed to prevent false certainty. They do not tell a reader what answer a clinician, plan, or pharmacy will give, and they do not promise a successful authorization or fill.

A neutral framework for the clinician and plan conversation

The comparison can be reduced to a sequence of evidence checks rather than a product verdict:

This sequence still does not choose a medicine. Its purpose is to keep unlike evidence layers from being blended into a conclusion they cannot support.

1. Define the clinical question before comparing brand names: type 2 diabetes, one of Ozempic’s specified additional risk-reduction indications, chronic weight management, or obesity-related moderate-to-severe OSA.
2. Match that question to the exact current brand-label language rather than to ingredient familiarity or social-media shorthand.
3. Keep SURMOUNT-5 attached to tirzepatide 10/15 mg, semaglutide 1.7/2.4 mg, and adults with obesity without type 2 diabetes.
4. Review the complete contraindications, boxed warning, warnings, interactions, and patient-counseling information with a licensed professional.
5. Bring a complete medicine list, allergy history, relevant family history, prior reactions, diagnoses, and planned procedures.
6. Ask the plan and pharmacy about the exact brand and indication without assuming label alignment guarantees access.
7. Recheck current official information if the label, policy, availability, or source date changes.

Bottom line

The clearest Ozempic vs Zepbound comparison begins with purpose, not a winner. Ozempic is a semaglutide diabetes brand with specified cardiovascular and chronic-kidney-disease risk-reduction indications in defined adult type 2 diabetes populations. Zepbound is a tirzepatide chronic weight-management and obesity-related OSA brand. [S1][S2]

SURMOUNT-5 adds head-to-head molecule evidence only within its tested regimens and adults-with-obesity-without-type-2-diabetes population. It should not be converted into a direct Ozempic brand claim. The complete current labels, personal history, other medicines, clinician judgment, and current plan rules remain separate decision inputs. [S3]

How we keep this page current

We record the official-source check date and keep factual statements tied to captured evidence. If a label, trial record, or access policy changes, the relevant statement must be rechecked before an update. We omit dynamic prices, and we include trial outcome figures only when an exact primary-source capture supports them.